logo
Twitter
Discord
Email
logo
Sera Prognostics, Inc.

Sera Prognostics, Inc.

NASDAQ•SERA
CEO: Ms. Evguenia Lindgardt M.B.A.
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 2021-07-15
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Contact Information
2749 East Parleys Way, Suite 200, Salt Lake City, UT, 84109, United States
801-990-0520
seraprognostics.com
Market Cap
$121.91M
P/E (TTM)
-4.9
25.7
Dividend Yield
--
52W High
$6.92
52W Low
$1.37
52W Range
34%
Rank56Top 81.7%
2.5
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 2.5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025

Financial Dashboard

Q3 2025 Data

Revenue

$16.00K-44.83%
4-Quarter Trend

EPS

-$0.16-33.33%
4-Quarter Trend

FCF

-$6.59M-9.94%
4-Quarter Trend

Earnings Highlights

Key Highlights

No Data Available

Risk Factors

No Data Available

Outlook

No Data Available

Peer Comparison

Revenue (TTM)

Lucid Diagnostics Inc.LUCD
$1.21B
+28885.2%
DocGo Inc.DCGO
$368.09M
-47.0%
Prenetics Global LimitedPRE
$69.04M
+171.7%

Gross Margin (Latest Quarter)

Vistagen Therapeutics, Inc.VTGN
100.0%
+0.0pp
Ovid Therapeutics Inc.OVID
87.1%
-12.9pp
Armata Pharmaceuticals, Inc.ARMP
68.1%
-21.4pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
PRE$243.91M-5.5-28.9%1.1%
ARMP$218.44M-4.670.3%198.5%
CNTX$166.30M-6.5-30.9%0.2%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-12.6%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 18, 2026
|
EPS:-$0.17
|
Revenue:-
Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 13, 2025|
    Revenue: $16.00K-44.8%
    |
    EPS: $-0.16-33.3%
    Meet
  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 6, 2025|
    Revenue: $17.00K-29.2%
    |
    EPS: $-0.16-36.0%
    Meet
  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 7, 2025|
    Revenue: $38.00K+0.0%
    |
    EPS: $-0.20-20.0%
    Meet
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 19, 2025|
    Revenue: $77.00K-74.8%
    |
    EPS: $-0.99+14.7%
    Miss
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 6, 2024|
    Revenue: $29.00K-31.0%
    |
    EPS: $-0.24+4.3%
    Miss
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 7, 2024|
    Revenue: $24.00K-80.5%
    |
    EPS: $-0.25-26.5%
    Meet
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 8, 2024|
    Revenue: $0.00-100.0%
    |
    EPS: $-0.25-21.9%
    N/A
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 20, 2024|
    Revenue: $306.00K+14.2%
    |
    EPS: $-1.16+18.9%
    Miss